Joining me on Healthcare Unfiltered is a trio of esteemed guests – Drs. Andy Evans, Matt Maurer, and Susan Parsons – of the HoLISTIC (Hodgkin Lymphoma International Study for Individual Care) Consortium.
In this riveting conversation, we delve into the consortium’s pioneering efforts, bringing together an international team of experts to scrutinize the multifaceted dimensions of Hodgkin lymphoma, spanning prognosis, epidemiology, treatment, survivorship, and health outcomes across all age groups. The discussion circles around consensus protocols for treatment, referral pathways, and clinical trials, probing the necessity of transplants in the era of novel therapeutics and the creation of predictive models tailored to individual patient needs.
Tune in to hear about the meticulous efforts invested in building the HoLISTIC portal, automating data migration, and navigating the challenges and progress in predictive modeling for treatment selection, response, and failure. This episode offers a captivating exploration of how collaboration, technology, and data analysis converge to shape the future of Hodgkin lymphoma care.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
